Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer

Launched by LONDON HEALTH SCIENCES CENTRE RESEARCH INSTITUTE OR LAWSON RESEARCH INSTITUTE OF ST. JOSEPH'S · Apr 13, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how personalized medicine can improve the way cancer patients respond to certain medications used for managing symptoms like nausea, pain, and depression. The researchers want to understand how individual differences in patients' genes might affect how well these medications work or cause side effects. Patients who participate will receive tailored recommendations based on their genetic information and other factors, aimed at optimizing their treatment. These recommendations will be provided during their clinic visits, and the researchers will follow up with them six months later to see how effective the changes have been.

To be eligible for the trial, participants need to be at least 18 years old, currently receiving chemotherapy, and taking specific medications for pain or depression. However, those who cannot complete the study surveys, are in palliative care, or have pre-existing conditions that affect the study's focus may not participate. Participants can expect to provide feedback on their symptoms before and after the personalized treatment recommendations to help the researchers assess the impact of this approach on their health and well-being.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older
• • Prescribed a chemotherapy medication
• • Currently taking one or more study medications (citalopram, escitalopram, venlafaxine, desvenlafaxine, codeine, oxycodone, hydrocodone, tramadol or ondansetron)
• Exclusion Criteria:
• • Patients who are unable to complete study materials (surveys) with or without assistance, including non-English speaking patients
• • Patients receiving palliative care
• • Patients taking anti-depressants for reason other than depression or anxiety, i.e. hot flash (Only applies to antidepressant cohort)
• • Patients with preexisting major depressive disorder prior to cancer diagnosis (Only applies to antidepressant cohort)